Raltegravir as Early Therapy in African-Americans Living With HIV Study
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a single arm, longitudinal study to examine the safety, tolerability, and
pharmacokinetic and metabolic characteristics of Raltegravir among 40 African-American,
HIV-infected, patients.
Phase:
Phase 1
Details
Lead Sponsor:
David A Wohl, MD
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Raltegravir Potassium Tenofovir